• About KoWi

    About KoWi

    KoWi is financed by the German Research Foundation (DFG) and provides you with information, advice and training on the wide range of EU research funding programmes.

    Read more
  • KoWi Services

    KoWi Services

    KoWi assists during the whole project cycle and offers one-stop support regarding all fields of EU research funding: strategic, topic-related, administrative.

    Read more
  • IMI 2 - Call 13

    IMI 2 - Call 13

    The Joint Undertaking Innovative Medicine (JU IMI2) has launched a new call for poposals. The total budget is EUR 223 mio.

    Read more
  • Work Programmes 2018+

    Work Programmes 2018+

    The European Commission published the H2020 Work Programme 2018-2020.

    Read more



IMI 2 launch of the 13th Call for proposals

08. Dec 2017

Last week the Innovative Medicines Initiative 2 (IMI 2) launched its 13th Call for proposals. The IMI 2 Call 13 encompasses a total of 15 topics:   

  • Topic 1: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches   
  • Topic 2: Genome-Environment Interactions in Inflammatory Skin Disease
  • Topic 3: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
  • Topic 4: Mitochondrial Dysfunction in Neurodegeneration
  • Topic 5: Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines InitiativeTopic 6: A sustainable European induced pluripotent stem cell platform
  • Topic 7: Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
  • Topic 8: Human tumour microenvironment immunoprofiling
  • Topic 9: ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now
  • Topic 10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system  
  • Topic 11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
  • Topic 12-15: Pilot programme on a Clinical Compound Bank for Repurposing: cardiovascular diseases and diabetes; respiratory diseases; neurodegenerative diseases; and rare/orphan diseases

Deadline for the submission of proposals in the first stage is 28 February 2018. Further information including the call text, as well as details on how to apply can be found on the call web page.

In addition IMI holds up to 15 December a series of webinars on each specific call topic and on IMI 2 rules and procedures.